These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 23263520)

  • 1. Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods.
    Chen MH; Willan AR
    Clin Trials; 2013 Feb; 10(1):54-62. PubMed ID: 23263520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal sample size determinations from an industry perspective based on the expected value of information.
    Willan AR
    Clin Trials; 2008; 5(6):587-94. PubMed ID: 19029207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods.
    Willan A; Kowgier M
    Clin Trials; 2008; 5(4):289-300. PubMed ID: 18697843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of information and optimal clinical trial design.
    Willan AR; Pinto EM
    Stat Med; 2005 Jun; 24(12):1791-806. PubMed ID: 15806619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accounting for between-study variation in incremental net benefit in value of information methodology.
    Willan AR; Eckermann S
    Health Econ; 2012 Oct; 21(10):1183-95. PubMed ID: 21882285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
    Kikuchi T; Gittins J
    Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugs.
    Patel NR; Ankolekar S
    Stat Med; 2007 Nov; 26(27):4976-88. PubMed ID: 17579924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of information analysis optimizing future trial design from a pilot study on catheter securement devices.
    Tuffaha HW; Reynolds H; Gordon LG; Rickard CM; Scuffham PA
    Clin Trials; 2014 Dec; 11(6):648-56. PubMed ID: 25084784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paradigms for adaptive statistical information designs: practical experiences and strategies.
    Wang SJ; Hung HM; O'Neill R
    Stat Med; 2012 Nov; 31(25):3011-23. PubMed ID: 22927234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Globally optimal trial design for local decision making.
    Eckermann S; Willan AR
    Health Econ; 2009 Feb; 18(2):203-16. PubMed ID: 18435429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of information methods for planning and analyzing clinical studies optimize decision making and research planning.
    Willan AR; Goeree R; Boutis K
    J Clin Epidemiol; 2012 Aug; 65(8):870-6. PubMed ID: 22609138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sample size determination for phase II clinical trials based on Bayesian decision theory.
    Stallard N
    Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
    Taylor DJ; Grobler A; Abdool Karim SS
    Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive two-stage designs in phase II clinical trials.
    Banerjee A; Tsiatis AA
    Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
    Wang SJ; Hung HM; O'Neill R
    J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An investment appraisal approach to clinical trial design.
    Backhouse ME
    Health Econ; 1998 Nov; 7(7):605-19. PubMed ID: 9845254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of information analyses of economic randomized controlled trials: the treatment of intermittent claudication.
    Groot Koerkamp B; Spronk S; Stijnen T; Hunink MG
    Value Health; 2010; 13(2):242-50. PubMed ID: 19818058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.